Plexiform Neurofibroma clinical trials at UC Health
1 research study open to new patients

  • Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

    open to eligible people ages 1 year and up

    This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults with NF1 and inoperable plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease in tumor volume reduction by 12 courses.

    at UCSF UCLA UCSD

Last updated: